Carbylan Therapeutics Inc Share Price Nasdaq
Equities
US1413841073
Pharmaceuticals
Sales 2024 * | - | Sales 2025 * | 14.95M 1.17B | Capitalization | 492M 38.64B |
---|---|---|---|---|---|
Net income 2024 * | -114M -8.95B | Net income 2025 * | -111M -8.71B | EV / Sales 2024 * | - |
Net cash position 2024 * | 218M 17.13B | Net cash position 2025 * | 105M 8.22B | EV / Sales 2025 * | 25.9 x |
P/E ratio 2024 * |
-3.84
x | P/E ratio 2025 * |
-4.83
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.77% |
Latest transcript on Carbylan Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 25/03/04 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 31/07/16 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 02/05/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 31/01/19 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 31/07/16 |
Albert Cha
BRD | Director/Board Member | 51 | 31/12/15 |
1st Jan change | Capi. | |
---|---|---|
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |